American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer

Abstract An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from six working groups, and a recent symposium co-sponsored by the ACS, American Society for Colposcopy and Cervical Pathology (ASCCP), and American Society for Clinical Pathology (ASCP), which was attended by 25 organizations. The new screening recommendations address age-appropriate screening strategies, including the use of cytology and high-risk human papillomavirus (HPV) testing, follow-up (e.g., management of screen positives and screening interval for screen negatives) of women after screening, age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16/18 infections.

[1]  ACOG Practice Bulletin no. 109: Cervical cytology screening. , 2009, Obstetrics and gynecology.

[2]  M. Sherman,et al.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000 , 2004, Cancer.

[3]  C. Meijer,et al.  PCR‐based high‐risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears , 1996, International journal of cancer.

[4]  J. Berkhof,et al.  Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening , 2008, British Journal of Cancer.

[5]  J. Mandelblatt,et al.  Gynecological care of elderly women. Another look at Papanicolaou smear testing. , 1986, JAMA.

[6]  M. Hakama,et al.  Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme , 2010, BMJ : British Medical Journal.

[7]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[8]  T. Gutteberg,et al.  Triage of Women with Minor Cervical Lesions: Data Suggesting a “Test and Treat” Approach for HPV E6/E7 mRNA Testing , 2010, PloS one.

[9]  T. Wright,et al.  2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests , 2007, Journal of lower genital tract disease.

[10]  F. Catalá-López,et al.  Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. , 2008, European journal of public health.

[11]  Joakim Dillner,et al.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer. , 2007, The New England journal of medicine.

[12]  P. Sasieni,et al.  Long‐term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia , 2006, International journal of cancer.

[13]  C. Wheeler,et al.  Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2 , 2009, Obstetrics and gynecology.

[14]  S. Wacholder,et al.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.

[15]  M. Plummer,et al.  Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology , 2010, International journal of cancer.

[16]  M. Stoler,et al.  Special commentary: patient safety and the next generation of HPV DNA tests. , 2010, American journal of clinical pathology.

[17]  C. Wheeler,et al.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years , 2009, The Lancet.

[18]  M. Manos,et al.  Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. , 2005, Journal of the National Cancer Institute.

[19]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[20]  S. Moss,et al.  The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  A. Chaturvedi,et al.  Hematologic and biochemical changes associated with human T lymphotropic virus type 1 infection in Jamaica: a report from the population-based blood donors study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  John T Brooks,et al.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  P. Remington,et al.  The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. , 2000, American journal of obstetrics and gynecology.

[24]  D. Simel,et al.  Cytologic screening after hysterectomy for benign disease. , 1995, American journal of obstetrics and gynecology.

[25]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[26]  W. Prendiville,et al.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.

[27]  A. Tos,et al.  Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. , 2005, American journal of clinical pathology.

[28]  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. , 2003, American journal of obstetrics and gynecology.

[29]  Marc Arbyn,et al.  Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors: A Randomized Controlled Trial , 2010 .

[30]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[31]  Diane Solomon,et al.  The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. , 2007, American journal of clinical pathology.

[32]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[33]  Marc Arbyn,et al.  Liquid Compared With Conventional Cervical Cytology: A Systematic Review and Meta-analysis , 2008, Obstetrics and gynecology.

[34]  A. Moscicki,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2002, CA: a cancer journal for clinicians.

[35]  Frequency of Cervical Smear Abnormalities Within 3 Years of Normal Cytology , 2000, Obstetrics and gynecology.

[36]  J. T. Cox,et al.  American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2007, CA: a cancer journal for clinicians.

[37]  H. Greenberg,et al.  Immunity and correlates of protection for rotavirus vaccines. , 2006, Vaccine.

[38]  M. Neyt,et al.  Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening , 2009, International Journal of Technology Assessment in Health Care.

[39]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[40]  三澤吉雄.  In Canada … , 1980, Current History.

[41]  N. Stout,et al.  Trade-offs in cervical cancer prevention: balancing benefits and risks. , 2008, Archives of internal medicine.

[42]  D. Roder,et al.  A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. , 2007, Sexual health.

[43]  David R. Scott,et al.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. , 2003, Journal of the National Cancer Institute.

[44]  C. Clavel,et al.  Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women , 1999, British Journal of Cancer.

[45]  J. Cuzick,et al.  Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. , 1996, British Journal of Cancer.

[46]  Mark Dignan,et al.  Cervical cancer prevention , 2010, Cancer.

[47]  S. Kulasingam,et al.  Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. , 2007, Vaccine.

[48]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[49]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[50]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[51]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[52]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[53]  X. Yi,et al.  Improved sensitivity of vaginal self‐collection and high‐risk human papillomavirus testing , 2012, International journal of cancer.

[54]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[55]  Interlaboratory reliability of Hybrid Capture 2. , 2004, American journal of clinical pathology.

[56]  Lisa M. Schwartz,et al.  Screening for cervical cancer: will women accept less? , 2005, The American journal of medicine.

[57]  H. Sigvaldason,et al.  The efficacy of HPV 16/18 vaccines on sexually active 18–23 year old women and the impact of HPV vaccination on organized cervical cancer screening , 2009, Acta obstetricia et gynecologica Scandinavica.

[58]  J. Cuzick,et al.  Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK , 2010, British Journal of Cancer.

[59]  J. Cuzick,et al.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories , 2003, British Journal of Cancer.

[60]  P. Castle,et al.  Practice improvement in cervical screening and management: symposium on management of cervical abnormalities in adolescents and young women. , 2010, Journal of lower genital tract disease.

[61]  P. Castle,et al.  Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting , 2009, Obstetrics and gynecology.

[62]  J. T. Cox,et al.  Practice Improvement in Cervical Screening and Management (PICSM): Symposium on Management of Cervical Abnormalities in Adolescents and Young Women , 2010, Journal of lower genital tract disease.

[63]  Zahava Berkowitz,et al.  Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? , 2010, Archives of internal medicine.

[64]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[65]  J. T. Cox,et al.  Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening , 2004, Obstetrics and gynecology.

[66]  K. Ault.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.

[67]  T. Wright,et al.  Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More , 2004, Obstetrics and gynecology.

[68]  T. Wright,et al.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. , 2011, American journal of clinical pathology.

[69]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[70]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[71]  C. McGahan,et al.  Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. , 2009, Journal of the National Cancer Institute.

[72]  F. X. Bosch,et al.  Cost-effectiveness of human papillomavirus vaccination and screening in Spain. , 2010, European journal of cancer.

[73]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[74]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[75]  P. Castle,et al.  Erratum: The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer (Obstet Gynecol (2010) 116 (76-84)) , 2010 .

[76]  P. Castle,et al.  The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer , 2010, Obstetrics and gynecology.

[77]  J. Green,et al.  Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies , 2007, International journal of cancer.

[78]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[79]  D. Ekwueme,et al.  The cost-effectiveness of male HPV vaccination in the United States. , 2011, Vaccine.

[80]  W. Prendiville,et al.  Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. , 2007, Gynecologic oncology.

[81]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[82]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[83]  C. Wheeler,et al.  Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.

[84]  M. Hagensee,et al.  Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. , 2008, Annals of internal medicine.

[85]  Joan L. Walker.  A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[86]  William D Mosher,et al.  Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. , 2005, Advance data.

[87]  Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. , 2004, The New England journal of medicine.

[88]  P. De Wals,et al.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. , 2007, Vaccine.

[89]  I. Gram,et al.  Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap‐smear in an opportunistic screening , 1998, Acta obstetricia et gynecologica Scandinavica.

[90]  Screening Interval and Risk of Invasive Squamous Cell Cervical Cancer , 2003, Obstetrics and gynecology.

[91]  Susun Bellew,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2010 .

[92]  A. P. Frank.  Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[93]  T. Wright,et al.  Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. , 2005, Journal of the National Cancer Institute.

[94]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[95]  G. Giles,et al.  Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. , 1995, British Journal of Cancer.

[96]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[97]  M. Cote,et al.  Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985–2003 , 2008, Cancer.

[98]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[99]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[100]  Diane Solomon,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2003, Journal of lower genital tract disease.

[101]  Chien-Jen Chen,et al.  Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. , 2011, Journal of the National Cancer Institute.

[102]  J. Salomon,et al.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. , 2008, Journal of the National Cancer Institute.

[103]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[104]  S. Rosso,et al.  Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. , 2008, The Lancet. Oncology.

[105]  T. Nolan,et al.  Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. , 1996, The New England journal of medicine.

[106]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[107]  A. Horvath,et al.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. , 2009, Clinical chemistry.

[108]  J. Cuzick,et al.  Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data , 2009, BMJ : British Medical Journal.

[109]  M. Hagensee,et al.  Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. , 2008, Annals of internal medicine.

[110]  J. Peto,et al.  Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort , 2004, British Journal of Cancer.

[111]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[112]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[113]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[114]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[115]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[116]  Elizabeth R Unger,et al.  Prevalence of HPV infection among females in the United States. , 2007, JAMA.

[117]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[118]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[119]  D. Ransohoff,et al.  New American Cancer Society process for creating trustworthy cancer screening guidelines. , 2011, JAMA.

[120]  C. Trimble,et al.  New technologies for cervical cancer screening. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[121]  Michael J. Thrall,et al.  High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. , 2010, American journal of clinical pathology.

[122]  Xavier Castellsagué,et al.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. , 2006, Journal of the National Cancer Institute.

[123]  P. Sweetnam,et al.  Long term follow up of women after hysterectomy with a history of pre‐invasive cancer of the cervix , 1992 .

[124]  Elizabeth R. Unger,et al.  The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions , 2011, Cancer Causes & Control.

[125]  L. Shulman.  Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. , 2007, The Journal of infectious diseases.

[126]  S. Wacholder,et al.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study , 2009, BMJ : British Medical Journal.

[127]  T. Wright,et al.  Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. , 2011, American journal of clinical pathology.

[128]  S. Piantadosi,et al.  Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype , 2005, Clinical Cancer Research.

[129]  F. Bray,et al.  Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.

[130]  M. Boily,et al.  Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries , 2009, Public Health Genomics.

[131]  J. Peto,et al.  A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. , 2011, European journal of cancer.

[132]  S. Kjaer,et al.  The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. , 2006, Cancer research.

[133]  S. Wacholder,et al.  Risk of Precancer and Follow-up Management Strategies for Women With Human Papillomavirus–Negative Atypical Squamous Cells of Undetermined Significance , 2007, Obstetrics and gynecology.

[134]  C. Peyton,et al.  Determinants of genital human papillomavirus detection in a US population. , 2001, The Journal of infectious diseases.

[135]  M. Plummer,et al.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. , 2007, The Journal of infectious diseases.

[136]  C. Wheeler,et al.  Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. , 2005, Journal of the National Cancer Institute.

[137]  S. Ciatto,et al.  Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case–control study in Florence , 2004, British Journal of Cancer.

[138]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[139]  H. Adami,et al.  International incidence rates of invasive cervical cancer after introduction of cytological screening , 1997, Cancer Causes & Control.

[140]  M. Mayrand,et al.  Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Québec, Canada , 2010, Canadian journal of public health = Revue canadienne de sante publique.

[141]  Gordon H Guyatt,et al.  Incorporating considerations of resources use into grading recommendations , 2008, BMJ : British Medical Journal.

[142]  M. Schiffman,et al.  The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. , 2007, American journal of clinical pathology.

[143]  References , 1971 .

[144]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[145]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[146]  E. Franco,et al.  The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. , 2009, Archives of medical research.

[147]  J. Berkhof,et al.  HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model‐based cost‐effectiveness , 2009, International journal of cancer.

[148]  David R. Scott,et al.  A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[149]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[150]  J. Cuzick,et al.  Further analysis of the ARTISTIC trial. , 2009, The Lancet Oncology.

[151]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[152]  E. Franco,et al.  Process of care failures in invasive cervical cancer: systematic review and meta-analysis. , 2007, Preventive medicine.

[153]  S. Coughlin,et al.  Assessing the Burden of HPV-Associated Cancers in the United States , 2008 .

[154]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[155]  P. Castle,et al.  Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. , 2011, Preventive medicine.

[156]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[157]  V Beral,et al.  The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.

[158]  M. Schiffman,et al.  Adding a test for human papillomavirus DNA to cervical-cancer screening. , 2003, The New England journal of medicine.

[159]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.